The cluster of C-suite insider sales, while small in absolute terms, is amplified by cross-filing context suggesting material corporate events may be pending. Monitor for upcoming earnings, partnership agreements, or equity offerings that could explain the timing. The CEO and CFO both selling in the same window is unusual and warrants close attention.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $66.44entry
- T+1 · 6mo ago +3.03%α +2.47% · $68.45
- T+5 · 6mo ago −1.44%α −1.91% · $65.48
- T+20 · 5mo ago +4.89%α +6.79% · $69.69
- T+60 · 3mo ago +24.83%α +22.95% · $82.94
Price Chart
How similar events traded
Executive Summary
Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day window. While the dollar amount is modest relative to the $13.5B market cap (0.009%), the cluster includes the top two C-suite executives and is amplified by cross-filing context suggesting proximity to earnings, agreements, or offerings.
Key Financial Metrics
Key Facts
- Three insiders sold a total of $1.24M in open-market sales from May 14-21, 2026.
- CEO Kumar Neil sold 2,256 shares at $67.57 for $152K.
- President and CFO Thomas Trimarchi sold 10,500 shares at $64.82 for $678K.
- Director Randal W. Scott sold 6,200 shares at $66.69 for $413K.
- Total sales represent 0.009% of BridgeBio's $13.5B market cap.
- Cross-filing context shows multiple amplifier signals for this cluster, including proximity to earnings, agreements, offerings, and press events.
Financial Impact
Total insider sales of $1.24M, or 0.009% of market cap.
Risk Factors
- Insider sales may signal management's view that the stock is fully valued or that near-term catalysts are uncertain.
- Cross-filing amplifier signals suggest potential upcoming corporate events (earnings, offerings, agreements) that could introduce volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BBIO-1779828894709 |
Track record
38 reports on BBIO
10 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers